Clinical Trial Detail

NCT ID NCT02135874
Title Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute leukemia

Therapies

Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Sorafenib + Vincristine Sulfate

Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Rituximab + Vincristine Sulfate

Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Vincristine Sulfate

Age Groups: adult senior

No variant requirements are available.